Market Research Reports and Industry Reports

ERS Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

ERS Genomics Ltd (ERS Genomics) is a provider of genomic editing technologies. The company offers clustered regularly interspaced short palindromic repeats (CRISPR), a proprietary technology which uses a complex molecule that contains protein cas9 with one or more guide ribonucleic acids that binds to the genome in living cells at any preferred locations. Its CRISPR technology can be used to change the deoxyribonucleic acid sequence at the targeted locations. It has intellectual property license for CRISPR-cas9 that can be used for genome editing in all the living organisms. The company offers non-exclusive licenses to other companies for internal research and sale of products and services in the areas of research tools, kits, reagents; molecular diagnostics, synthetic biology, and others. ERS Genomics is headquartered in Dublin, Ireland.

ERS Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

3
List of Tables 4
List of Figures 4
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Licensing Agreements 9
Oxford Genetics Enters into Licensing Agreement with ERS Genomics 9
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 10
Horizon Discovery Extends Licensing Agreement with ERS Genomics 12
Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 13
Bayer Enters into Licensing Agreement with ERS Genomics 14
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 15
ERS Genomics Ltd - Key Competitors 16
ERS Genomics Ltd - Key Employees 17
ERS Genomics Ltd - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Jun 01, 2016: ERS Genomics Appoints Eric Rhodes as Chief Executive Officer 19
Legal and Regulatory 20
Apr 13, 2017: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List Of Tables

List of Tables
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Oxford Genetics Enters into Licensing Agreement with ERS Genomics 9
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 10
Horizon Discovery Extends Licensing Agreement with ERS Genomics 12
Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 13
Bayer Enters into Licensing Agreement with ERS Genomics 14
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 15
ERS Genomics Ltd, Key Competitors 16
ERS Genomics Ltd, Key Employees 17

Global Track Loaders Market Professional Survey Report 2017

This report studies Track Loaders in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

USD 3500View Report

Global Concrete Pavers Market Professional Survey Report 2017

This report studies Concrete Pavers in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

USD 3500View Report

Rosetta Genomics Ltd (ROSG) - Product Pipeline Analysis, 2017 Update

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast,

USD 750View Report

Rosetta Genomics Ltd (ROSG) - Medical Equipment - Deals and Alliances Profile.

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast,

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Nov 2017
No. of Pages :21
Country :Ireland
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube